Kenvue (NYSE:KVUE) Releases Quarterly Earnings Results, Meets Expectations

Kenvue (NYSE:KVUE) issued its quarterly earnings data on Friday. The company reported $0.29 earnings per share for the quarter, hitting the consensus estimate of $0.29, FiscalAI reports. The company had revenue of $3.89 billion for the quarter, compared to analysts’ expectations of $3.86 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. Kenvue’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.28 earnings per share.

Kenvue Trading Down 1.5%

Shares of KVUE traded down $0.30 during trading hours on Friday, hitting $19.26. 66,595,389 shares of the stock were exchanged, compared to its average volume of 18,307,464. Kenvue has a fifty-two week low of $14.06 and a fifty-two week high of $20.13. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.01 and a quick ratio of 0.71. The business has a 50-day moving average of $18.40 and a 200-day moving average of $18.19. The firm has a market capitalization of $36.99 billion, a P/E ratio of 22.14, a price-to-earnings-growth ratio of 1.79 and a beta of 0.48.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 2nd. Stockholders of record on Monday, September 21st were given a dividend of $0.21 per share. The ex-dividend date was Monday, September 21st. This represents a $0.84 annualized dividend and a dividend yield of 4.4%. Kenvue’s dividend payout ratio is 96.55%.

More Kenvue News

Here are the key news stories impacting Kenvue this week:

• Positive Sentiment: Revenue increased 3.2% year over year to $3.89 billion, exceeding the roughly $3.86 billion consensus estimate. Management cited continued growth in Self Care and Essential Health, productivity initiatives, margin expansion and strong cash generation. Kenvue Reports Third Quarter 2026 Results
• Positive Sentiment: Reported earnings were $0.29 per share, up from $0.28 a year earlier. Zacks characterized the result as slightly ahead of its $0.28 consensus estimate, while other coverage said profit fell short of expectations, suggesting the market is focused on the exact earnings measure and guidance. Kenvue Surpasses Q3 Earnings Estimates
• Positive Sentiment: The quarterly performance represents Kenvue’s fourth consecutive quarter of net and organic sales growth, supporting management’s efforts to rebuild momentum across its consumer-health brands. Kenvue Profit, Revenue Rise as Turnaround Efforts Continue
• Neutral Sentiment: Kenvue’s results arrive as its approximately $40 billion acquisition by Kimberly-Clark approaches closing. The deal may provide strategic support, but investors remain focused on execution, integration and the turnaround’s durability. Kenvue Q3 2026 Revenue Beats as Kimberly-Clark Deal Nears Close
• Negative Sentiment: The conflicting earnings headlines indicate that profit performance did not clearly exceed investor expectations, even though revenue beat forecasts. Earlier concerns about inflation and cautious consumer spending also remain potential pressures on margins and demand. Kenvue Misses Third-Quarter Profit Expectations

Wall Street Analysts Forecast Growth

Several brokerages have commented on KVUE. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kenvue in a report on Friday, September 11th. Zacks Research lowered Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. UBS Group decreased their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Tuesday, August 11th. HSBC lowered their price objective on Kenvue from $20.00 to $19.00 and set a “hold” rating for the company in a research report on Monday, August 10th. Finally, Wall Street Zen downgraded Kenvue from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Thirteen research analysts have rated the stock with a Hold rating. Based on data from MarketBeat.com, Kenvue presently has an average rating of “Hold” and a consensus target price of $19.33.

About Kenvue

Kenvue Inc is a consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, and essential health products, serving consumers through retail, e-commerce and other distribution channels.

The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; and Listerine, Johnson’s and OGX in oral care, baby care and hair care.